Medicenna Therapeutics (TSE:MDNA) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of C$1.79 and traded as low as C$0.93. Medicenna Therapeutics shares last traded at C$1.03, with a volume of 129,478 shares trading hands.

Medicenna Therapeutics Price Performance

The company has a market cap of C$74.07 million, a P/E ratio of -2.73 and a beta of 1.21. The company has a 50 day moving average of C$1.29 and a 200-day moving average of C$1.77. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65.

Insider Transactions at Medicenna Therapeutics

In other Medicenna Therapeutics news, Senior Officer David Hyman acquired 20,000 shares of the business's stock in a transaction dated Thursday, January 9th. The stock was bought at an average price of C$1.45 per share, with a total value of C$29,000.00. 22.57% of the stock is owned by insiders.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.